"Somos un equipo humano que intenta lograr que cada paciente se sienta acompañado y aprecie ante todo la calidez en la atención, el compromiso hacia los derechos del individuo y la pasión por la salud. El equipamiento más sofisticado toma valor por las manos que lo manejan, la calidad con que lo hacen y la humanidad que transmiten."

During the past decade, Instituto Médico Río Cuarto conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 4 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 3 clinical trials were completed. i.e. 15.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto Médico Río Cuarto" #1 sponsor was "Eli Lilly and Company" with 7 trials, followed by "Hoffmann-La Roche" with 3 trials sponsored, "Janssen Research & Development, LLC" with 3 trials sponsored, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 2 trials sponsored and "Merck Sharp & Dohme LLC" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto Médico Río Cuarto" #1 collaborator was "Atea Pharmaceuticals, Inc." with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Instituto Médico Río Cuarto" are "COVID-19" (2 trials), "Covid19" (2 trials), "Heart Failure With Preserved Ejection Fraction" (2 trials), "Neoplasm Metastasis" (2 trials) and "Obesity" (2 trials). Many other conditions were trialed in "Instituto Médico Río Cuarto" in a lesser frequency.

Most popular intervention types in "Instituto Médico Río Cuarto" are "Drug" (21 trials), "Biological" (5 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Pembrolizumab" (3 trials), "Abemaciclib" (2 trials), "Atezolizumab" (2 trials) and "Carboplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Instituto Médico Río Cuarto" are 23 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Instituto Médico Río Cuarto". undefined are not yet recruiting, 13 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Instituto Médico Río Cuarto, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto Médico Río Cuarto, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".